clofibric acid and Osteoporosis

clofibric acid has been researched along with Osteoporosis in 1 studies

Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.

Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.

Research

Studies (1)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Gastrointestinal Symptoms

Total number of patients with gastrointestinal symptoms at the end of follow-up at day 40.Those symptoms perceived abdominal region (pain, burn, pressure, nausea, vomiting) (NCT04507867)
Timeframe: Day 40

Hidric Balance on Day 3

The ratio between the water assimilated into the body and that lost from the body, in milliliters. (NCT04507867)
Timeframe: It is evaluated on day 3 of hospital stay (duration approximately 10 minutes).

Mortality in Intubated Patients at Day 40

Patients who were intubated during their hospital stay and died before completing follow-up on day 40. (NCT04507867)
Timeframe: 40 days

Need for Home Oxygen Flow

The need to continue with supplemental oxygen at hospital discharge. Categories: 1. Yes, 2. No. (NCT04507867)
Timeframe: Day 40

Number of Deceased Participants Stratified by Leukocytes Level

Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline

Number of Deceased Participants Stratified by Neutrophils Level

Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline

Number of Deceased Participants Stratified by RCP Level

Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline

Number of Deceased Participants Stratified by Urea Level

Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline

Number of Deceased Patients Stratified by Fibrinogen Level.

Association between the presentation of certain laboratory parameters taken at baseline with the overall mortality of discharged patients compared to deceased patients. (NCT04507867)
Timeframe: Baseline

Number of Deceased Patients Stratified by Procalcitonin Level.

Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline

Number of Deceased Patients Stratified by Ureic Nitrogen Level

Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline

Number of Defectations on Day 3

Refers to the subjective sensation of increased abdominal pressure without an increase in abdominal size, the number of defecations were quantified at day 3 and compared between both groups. (NCT04507867)
Timeframe: Day 3

Number of Participants With Distension on Day 3

Is a visible increase in abdominal girth.1. Present, 2. Absent. (NCT04507867)
Timeframe: Day 3

Overall Mortality at Day 40

Total number of patients who died before day 40 of follow-up. (NCT04507867)
Timeframe: 40 days.

Overall Survival

Overall survival, the total number of patients included in the study and completed a 40-day follow-up. (NCT04507867)
Timeframe: 40 days.

Oxigen Saturation >90% on Day 3

the total number of patients with oxygen saturation >90% on day 3 of their hospital stay. (NCT04507867)
Timeframe: day 3.

Participants With Normal Bristol Scale at Day 3

"The Bristol Stool Form Scale categorizes stools into one of seven stool types ranging from type 1 (hard lumps) to type 7 (watery diarrhea). Type 3 and 4 were considered Normal." (NCT04507867)
Timeframe: day 3

Post Covid Syndrome

Persistence of clinical signs and symptoms that arise after developing COVID-19, and are not explained by an alternative diagnosis. 1. Present. 2. Absent. (NCT04507867)
Timeframe: Day 40.

Progression to Mechanical Ventilation Assistance

total number of patients included in the study who progressed to mechanical ventilation during the first 10 days of hospital stay. (NCT04507867)
Timeframe: 10 days.

Saturation Without Supplementary Oxygen

The oxygen saturation without supplementary oxygen is taken at the control appointment 40 days after hospital discharge. (NCT04507867)
Timeframe: day 40

Survival in Intubated Patients at Day 40

Total number of patients who were intubated, extubated, discharged and completes the 40 day follow-up (NCT04507867)
Timeframe: 40 days

Time of Home Oxigen Use

It is recorded for how many days the treating doctor asked the patients to continue to administer supplemental oxygen after hospital discharge (NCT04507867)
Timeframe: day 40

Weight Decrease

Is defined as at least a 5% reduction in weight from the baseline level.Total number of patients with weight loss at the end of follow-up at day 40 (NCT04507867)
Timeframe: Day 40

Oxigen Flow (Intragroup)

Difference in oxygen delivery between the baseline period and day 3 of hospital stay in each group. (NCT04507867)
Timeframe: baseline and day 3

PHQ-9 Test

Is a self-administered version of the PRIME-MD diagnostic instrument for common mental disorders, includes 9 items, which evaluate the presence of depressive symptoms based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders version 4, during the last 2 weeks, how often the patient presented depressive symptoms. According to the sum of the score obtained, the following 4 categories will be considered: 0-4 minimum existence or absence of depressive symptoms; 5-9 = mild depressive symptoms; 10-14 = moderate depressive symptoms; 15-19 = moderate to severe depressive symptoms; 20-27 = severe depressive symptoms. (NCT04507867)
Timeframe: baseline and hospital discharge

qSOFA at Day 3

Quick-Sequential Organ Failure Assessment (qSOFA) score gives 0 to 3 points. ≥2 in the setting of suspected infection had a high predicted in-hospital mortality rate and could be considered septic. (NCT04507867)
Timeframe: Baseline and Day 3

Reviews

1 review available for clofibric acid and Osteoporosis